Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 4 Interventional Results available

Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis

ClinicalTrials.gov ID: NCT03389893

Public ClinicalTrials.gov record NCT03389893. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 9:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis, Dupilumab Study

Study identification

NCT ID
NCT03389893
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 4
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Enrollment
72 participants

Conditions and interventions

Interventions

  • Dupilumab Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 24, 2018
Primary completion
Apr 2, 2020
Completion
Sep 8, 2020
Last update posted
Oct 3, 2021

2018 – 2020

United States locations

U.S. sites
9
U.S. states
7
U.S. cities
9
Facility City State ZIP Site status
University of California San Diego La Jolla California 92093
Children's Hospital Los Angeles Los Angeles California 90027
Stanford University Stanford California 94305
National Jewish Health Denver Colorado 80206
University of Florida Gainesville Florida 32611
University of Rochester Medical Center Rochester New York 14642
Duke University Durham North Carolina 27710
Oregon Health Sciences University Portland Oregon 97239
University of Pennsylvania Philadelphia Pennsylvania 19104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03389893, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 3, 2021 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03389893 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →